Gavila, J., Oliveira, M., Pascual, T., Perez-Garcia, J., Gonzalez, X., Canes, J., . . . Prat, A. (2019). Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): An open-label, single-group, multicenter, phase 2 trial.
Citação norma ChicagoGavila, Joaquin, et al. Safety, Activity, and Molecular Heterogeneity Following Neoadjuvant Non-pegylated Liposomal Doxorubicin, Paclitaxel, Trastuzumab, and Pertuzumab in HER2-positive Breast Cancer (Opti-HER HEART): An Open-label, Single-group, Multicenter, Phase 2 Trial. 2019.
Citação norma MLAGavila, Joaquin, et al. Safety, Activity, and Molecular Heterogeneity Following Neoadjuvant Non-pegylated Liposomal Doxorubicin, Paclitaxel, Trastuzumab, and Pertuzumab in HER2-positive Breast Cancer (Opti-HER HEART): An Open-label, Single-group, Multicenter, Phase 2 Trial. 2019.